

9 April 2024

Health House Australia and Corporate Update

Highlights:

- Health House Australia announces the planned launch of its medicinal cannabis clinic in Q2 of 2024
- The group is also pleased to announce that it has added several new suppliers during Q1 of 2024
- Health House Australia was a key contributor to Melodiol group FY 2023 revenues of \$21.6m (an increase of 148% on FY 2022)
- Health House Australia and Health House UK contributed \$11.5m to group FY 23 revenues
- Placement completed to fund working capital requirements

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that its wholly owned Australian subsidiary, Health House Australia, continues to make strong operational progress.

Over the past several months, Health House Australia has undertaken significant internal analysis and planning for the launch of its medicinal cannabis clinic. Health House Australia expects the Health House Wellness Clinic to be operational in Q2 of 2024 and views this activity as a key strategic objective. The operation of the Health House Wellness Clinic is expected to significantly extend Health House Australia's value proposition to existing and prospective suppliers. The ability to attract and add new suppliers to the group's portfolio is a significant driver of the group's ability to grow revenues.

During Q1 of 2024, Health House Australia successfully added several new suppliers to its existing base. These include Botanitech, Chemovar, Endoca, Quantum, and MedTEC Pharma's announcement of Health House Australia as its lead launch partner on the introduction of their Australian-grown flower and oil medicines, slated for Q2 of 2024. The continued addition of new suppliers to its portfolio is a core strategic objective of Health House Australia.

Management commentary:

CEO and Managing Director, Mr William Lay said: *"Since being Australia's first company to import medicinal cannabis in 2017, Health House Australia's unwavering commitment to great service and integrity has led to it becoming one of the trusted names within the distribution of medical cannabis in Australia. I am very proud of our team for their hard work to remain a supplier of choice for existing relationships, and for continuing to expand the supplier base. Additionally, we are very excited about the launch of Health House's medical cannabis clinic in Q2 of 2024, which will serve to further strengthen Health House Australia's value proposition to existing and new suppliers."*

Placement:

The Company advises that it has received firm commitments to raise \$796,000 (before costs) through the issue of approximately 180,090,498 new fully paid ordinary shares ('Shares') at an issue price of \$0.00442 per Share (the 'Placement').

The Company will issue 101,357,466 shares today, representing \$488,000 of the placement proceeds, with the remainder to be completed on a deferred settlement basis no later than 16 April 2024. Please refer to the Company's Appendix 2A and Appendix 3B lodged today for further details on the placement.

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.